GYRE THERAPEUTICS, INC. (GYRE) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
GYRE THERAPEUTICS, INC. (GYRE)
A forensic read on GYRE THERAPEUTICS, INC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
7.1
Altman Z-score
Watch
Earnings quality
6
Forensic signals
-6.3%
ROE
$701M
Market cap
GYRE THERAPEUTICS, INC. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 7.1, placing it in the Safe zone. 6 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
97d DSOReceivables vs revenue.Days sales outstanding moved from 68 to 97 days FY2024→FY2025 (receivables +59% vs revenue +10%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
596dInventory days.Days inventory outstanding moved from 337 to 596 FY2023→FY2024 (against cost of goods sold; inventory +48% vs -16% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
7%Return on invested capital.Return on invested capital is 7% and slipping from 11% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+12.1%/yrShare-count dilution.Diluted share count changed +36% over the last 3 years to FY2025 (+12.1%/yr). The count is GROWING — existing holders are being diluted. That's ~12.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~36%.
791% of FCFShareholder returns.Returned $45M to shareholders (buybacks + dividends) in FY2022 — 791% of free cash flow. More than free cash flow generated — and beyond operating cash too, so the extra is coming from debt or cash reserves, which isn't sustainable indefinitely.
+19.4%Accruals ratio.Net operating assets grew +19.4% relative to their average in FY2025 — the accrual component of earnings. Accruals are building faster than is comfortable — part of profit sits in receivables, inventory or capitalized costs rather than cash. The cash-flow cross-check agrees: reported earnings ran ahead of operating cash by +9% of net operating assets.
Key fundamentals
Net Margin8.5%
Debt / Equity0.01x
Free Cash Flow-180000.00
Latest Revenue$116.6M
Return on Equity9.3%
Revenue Growth YoY+10.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on GYRE THERAPEUTICS, INC.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about GYRE's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown